DRAPER, Utah, April 04, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity") released the findings of a new survey on Artificial Intelligence (AI) in benefits administration. The survey provides a benchmark on senior benefit leaders’ attitude toward AI-enabled benefits tools.
A majority (73%) of the more than 800 respondents surveyed believe that AI will have a positive influence on benefits administration. Of the VP and Director-level benefits leaders surveyed only 31% believed they are knowledgeable about the AI solutions in the market.
"Benefits leaders, like many professionals are learning about what these new technologies can do and they’re optimistic, but they’re also realistic," said Shuki Licht, vice president of Innovation at HealthEquity. “Consumer-facing AI products have opened the door to creating better member outcomes, one that we’re excited about is simplifying the claims process. It’s an exciting time but it’s important that companies using AI are transparent so everyone can feel confident about the results.”
Conducted in February, the survey was administered via Qualtrics to a pool of Directors and VPs of Total Rewards to better understand benefit leader AI perspectives. Additional findings included:
“These results will help the industry to better understand the places to build, and where to tread cautiously with new AI technology," said Jess Cloud, vice president of IT Operations and Transformation at HealthEquity. "We’re going to be strategic with our use of AI insights to drive macro-level improvements at HealthEquity, while protecting our members. Our aim is to utilize the technology to reduce friction points and save time, two areas that are always challenging in the US healthcare system."
Survey results, further insights and recommendations can be found on the HealthEquity Remark blog.
About HealthEquity
HealthEquity and its subsidiaries administer Health Savings Accounts (HSAs) and various other consumer-directed benefits for over 15 million accounts, working in close partnership with employers, benefits advisors, and health and retirement plan providers who share our unwavering commitment to save and improve lives by empowering consumer healthcare. Through cutting-edge solutions, innovation, and a relentless focus on improving health outcomes, we empower individuals to take control of their healthcare journey while ultimately enhancing their overall well-being. Learn more about our “Purple service” and approach at www.healthequity.com
Media Contact:
Amy Cerny
Director of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$91.54 |
Daily Change: | 0.45 0.49 |
Daily Volume: | 920,155 |
Market Cap: | US$7.930B |
November 12, 2024 October 15, 2024 September 03, 2024 September 03, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB